[Application of secretary luciferase labeled orthotopic transplant model of hepatocellular carcinoma to evaluate tumor response to interferon-beta gene therapy]

Sheng Wu Gong Cheng Xue Bao. 2012 Oct;28(10):1236-44.
[Article in Chinese]

Abstract

To establish an orthotopic transplant mouse model of hepatocellular carcinoma (HCC) labeled with secretary luciferase and to study its response to anti-tumor treatment with interferon-beta gene therapy. We labeled the murine hepatoma Hepal-6 cells with secretary Gaussia princeps luciferase (Gluc), and then injected Gluc labeled Hepal-6 cells intrasplenically in C57BL/6 mice. We monitored blood Glue to evaluate the tumor development and anti-tumor effects of hydrodynamic injection with interferon-beta expressing plasmid. We successfully established the orthotopic mouse model of HCC by intrasplenic injection of Glue labeled Hepal-6 cells. The Glue blood assay could reflect the amount of cancer cells in vivo, tumor progression, as well as anti-tumor effect of interferon-beta gene therapy. In conclusion, Gluc labeled orthotopic transplant mouse model of HCC can ex vivo real-time monitor the tumor development and tumor response to treatments.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / therapy*
  • Cell Line, Tumor
  • Genes, Reporter
  • Genetic Therapy
  • Interferon-beta / genetics*
  • Interferon-beta / therapeutic use*
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*
  • Luciferases / blood
  • Luciferases / genetics*
  • Luciferases / metabolism
  • Mice
  • Mice, Inbred C57BL
  • Neoplasm Transplantation
  • Treatment Outcome

Substances

  • Interferon-beta
  • Luciferases